Evidence map›Paper›PMID 33310350›Full record

ArticleNuclear medicine and biology2021

Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.

Kim H Kwan, Ingrid J G Burvenich, Margaret M Centenera, Yit Wooi Goh, Angela Rigopoulos, Jonas Dehairs, Johannes V Swinnen, Ganesh V Raj, Andrew J Hoy, Lisa M Butler and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Kim H KwanSchool of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Australia.
Ingrid J G BurvenichTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia. Electronic address: Ingrid.burvenich@onjcri.org.au.
Margaret M CenteneraAdelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia.
Yit Wooi GohTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.
Angela RigopoulosTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Jonas DehairsLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI - Leuven Cancer Institute, KU Leuven - University of Leuven, Leuven, Belgium.
Johannes V SwinnenLaboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI - Leuven Cancer Institute, KU Leuven - University of Leuven, Leuven, Belgium.
Ganesh V RajDepartment of Urology, UT Southwestern Medical Center at Dallas, TX, USA; Department of Pharmacology, UT Southwestern Medical Center at Dallas, TX, USA.
Andrew J HoySchool of Medical Sciences, The University of Sydney, Sydney, Australia.
Lisa M ButlerAdelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia.
Andrew M ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia; Department of Medicine, Melbourne University, Melbourne, Australia.
Jonathan M WhiteSchool of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Australia.
Uwe AckermannTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia; Department of Medicine, Melbourne University, Melbourne, Australia. Electronic address: uwea@unimelb.edu.au.
Olivia Newton-John Cancer Wellness & Research Centre · AUKU Leuven · BEUniversity of Adelaide · AUUniversity of Melbourne · AUAustin Health · AULa Trobe University · AUSouthwestern Medical CenterUniversity of Sydney · AU

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

introductionAltered lipid metabolism and subsequent changes in cellular lipid composition have been observed in prostate cancer cells, are associated with poor clinical outcome, and are promising targets for metabolic therapies. This study reports for the first time on the synthesis of a phospholipid radiotracer based on the phospholipid 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine (PC44:12) to allow tracking of polyunsaturated lipid tumor uptake via PET imaging. This tracer may aid in the development of strategies to modulate response to therapies targeting lipid metabolism in prostate cancer.

methodsLipidomics analysis of prostate tumor explants and LNCaP tumor cells were used to identify PC44:12 as a potential phospholipid candidate for radiotracer development. Synthesis of phosphocholine precursor and non-radioactive standard were optimised using click chemistry. The biodistribution of a fluorine-18 labeled analogue, N-{[4-(2-[

results[ CONCLUSIONS AND ADVANCES IN KNOWLEDGE: This study demonstrates the ability to radiolabel phospholipids and indicates the potential to monitor the in vivo distribution of phospholipids using fluorine-18 based PET.

Indexed as

Fluorine RadioisotopesIsotope LabelingPositron-Emission TomographyProstatic NeoplasmsAnimalsCell Line, TumorChemistry Techniques, SyntheticHumansMaleMicePhospholipidsRadiochemistryTissue DistributionFluorine-18Fluorine RadioisotopesPhospholipidsFluorine-18Lipid metabolismPETPhospholipidProstate cancer

Identifiers

PMID33310350
PMCPMC8071757
OpenAlexW3110247784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.